OneSkin OS-01 FACE review: what the peptide-free comparison adds

The product page shows OS-01 FACE at $117 for a one-time purchase and $100 under a subscription display, beside 15% savings language. It describes a 50 mL product and options to skip or cancel recurring orders. Those are the captured offer terms, rather than a verified transaction or a promise that the display will remain unchanged. OneSkin product.

The named format matters when reading the evidence: this is the facial moisturizer record. Its quantity and purchase options do not establish a clinical course or a replacement for prescribed estriol. The face-care comparison includes different types of facial-care records without treating their routes, ingredients or purposes as equivalent.

The complete captured ingredient list identifies Decapeptide-52 as the proprietary OS-01 peptide. It also names ingredients including glycerin, squalane, niacinamide and sodium hyaluronate. That full list allows the product to be identified beyond its peptide branding, although it does not give a finished-product concentration for the peptide. OneSkin product.

Estriol is not named in that declaration. This is a statement about the list, not an independent hormone assay or a guarantee about every bottle. For neutral comparison reading, the Paula’s Choice moisturizer review examines another named product without implying that shared ingredient categories create identical formulas or results.

The company describes a double-blind, split-face study involving 22 women over 12 weeks. The comparator was an otherwise identical formulation without OS-01. This design helps ask a narrower question: whether the peptide-containing cream differed from its vehicle, rather than whether a moisturizer did anything compared with no moisturizer. OneSkin product, OneSkin study summary.

The description is useful, but it is still the company’s account. We did not read the complete linked paper, verify the participant records or independently inspect the formulations. The control makes some interpretations more precise; it does not remove the need to examine which endpoint actually favored the peptide-containing side.

The product narrative gives ages 47–65. Two product footnotes instead give 54–64 and 54–65. Those ranges cannot all be silently treated as one identical description. The study summary also refers to assessments at zero, three and six months, which does not readily match its description of a 12-week study. OneSkin product, OneSkin study summary.

These discrepancies do not establish that no study occurred. They do leave the exact enrolled group and assessment schedule unresolved in the public account. A complete report that explains the versions would be more useful than choosing the most convenient range. The before-and-after photo guide offers a related way to question the context around visible results.

The summary reports perceived hydration improvement in both formulations: 100% at six weeks and 84% at 12 weeks. It also describes softness gains with both. Those shared results should not all be credited to OS-01. They show why the peptide-free vehicle matters when the visible benefit being discussed is moisture or softness. OneSkin study summary, American Academy of Dermatology Wrinkle remedies.

AAD explains that moisturizing can reduce the appearance of some fine lines by helping skin retain water. That professional context helps interpret a hydration result, but does not confirm OneSkin’s trial or explain every endpoint. Our hydration and firmness guide keeps moisture-related appearance separate from a claim about structural or age-related change.

The product page gives barrier-improvement figures of 19% at six weeks and 14% at 12 weeks. The summary gives transepidermal water-loss reductions of 14% and 18%, respectively. These are differently described measures and figures. We do not convert one into the other or average them into a single result. OneSkin product, OneSkin study summary, Federal Trade Commission Health Products Compliance Guidance.

Likewise, the summary describes wrinkle indentation at six weeks as close to statistical significance; that is not a report that every wrinkle endpoint was significant. FTC guidance emphasizes matching the advertised result to the tested outcome. For this moisturizer, that means preserving both the specific endpoint and the uncertainty in its public description.

The study summary was updated June 16, 2025 and names OneSkin’s chief scientific officer and cofounder Alessandra Zonari as reviewer. That identifies the company expertise behind the account. It is not independent medical review of this publication, and it does not mean that we acquired the full study or its underlying data. OneSkin study summary, Federal Trade Commission Health Products Compliance Guidance.

The clearest next question concerns the complete report matching this formula, participant group and schedule. The SkinMedica serum review is another record to read for its own endpoint language. Here, the vehicle comparison adds useful detail, while the conflicting versions and shared hydration gains prevent a simple peptide-only conclusion.